Chair of Endocrinology, University of Milan, Ospedale San Luca IRCCS, Istituto Auxologico Italiano, Milan, Italy.
J Neuroendocrinol. 2010 Apr;22(4):294-300. doi: 10.1111/j.1365-2826.2010.01959.x. Epub 2010 Jan 27.
Prepro-thyrotrophin-releasing hormone (TRH) (178-199), a 22-amino acid cleavage product of the TRH prohormone, has been postulated to act as an adrenocorticotrophin hormone (ACTH)-release inhibitor. Indeed, although in vitro evidence indicates that this peptide may inhibit basal and stimulated ACTH secretion in rodent anterior pituitary primary cultures and cell lines, not all studies concur and no study has as yet evaluated the effect of this peptide in Cushing's disease. The present study aimed to test the effect of preproTRH(178-199) in human tumoural corticotrophs. Twenty-four human ACTH-secreting pituitary tumours (13 macroadenomas, 11 microadenomas) were collected during surgery and incubated with 10 or 100 nm preproTRH(178-199). ACTH secretion was assessed after 4 and 24 h of incubation by immunometric assay and expressed relative to levels observed in control, unchallenged wells (= 100%). Parallel experiments were performed in rat anterior pituitary primary cultures. A clear inhibition of ACTH secretion at 4 and 24 h was observed in 12 specimens (for 10 nm ppTRH: 70 +/- 4% control at 4 h and 83 +/- 5% control at 24 h; for 100 nm ppTRH: 70 +/- 4% control at 4 h and 85 +/- 5% control at 24 h), whereas a mild and short-lasting stimulatory effect was observed in three tumours and no changes in ACTH secretion in the remaining nine tumoural specimens. The inhibitory effect of preproTRH(178-199) was more evident in macroadenomas and significantly correlated with sensitivity to dexamethasone inhibition. Significant inhibition of ACTH secretion by preproTRH(178-199) in rat pituitary cultures was observed after 24 h of incubation. The present study conducted in a large series of human corticotroph tumours shows that preproTRH(178-199) inhibits tumoural ACTH secretion in a sizable proportion of specimens, in close relation to the size of the tumour and its sensitivity to glucocorticoid negative feedback. This appears a promising avenue of research and further studies are warranted to explore the full scope of preproTRH(178-199) as a regulator of ACTH secretion.
促甲状腺激素释放激素前体(TRH)(178-199),TRH 前体的 22 个氨基酸切割产物,被假定为 ACTH 释放抑制剂。事实上,尽管体外证据表明,这种肽可能抑制啮齿动物垂体前叶原代培养物和细胞系中的基础和刺激 ACTH 分泌,但并非所有研究都一致,也没有研究评估这种肽在库欣病中的作用。本研究旨在检测 preproTRH(178-199) 在人肿瘤促肾上腺皮质激素细胞中的作用。在手术期间收集了 24 个人类 ACTH 分泌垂体肿瘤(13 个大腺瘤,11 个微腺瘤),并用 10 或 100nm preproTRH(178-199) 孵育。孵育 4 和 24 小时后,通过免疫测定法评估 ACTH 分泌,并相对于对照未刺激孔中的水平表示(=100%)。在大鼠垂体前叶原代培养物中进行了平行实验。在 12 个标本中观察到 ACTH 分泌在 4 和 24 小时时明显抑制(对于 10nm ppTRH:4 小时时为 70 +/- 4%对照,24 小时时为 83 +/- 5%对照;对于 100nm ppTRH:4 小时时为 70 +/- 4%对照,24 小时时为 85 +/- 5%对照),而在三个肿瘤中观察到轻度且短暂的刺激作用,在其余九个肿瘤标本中 ACTH 分泌无变化。preproTRH(178-199) 的抑制作用在大腺瘤中更为明显,并且与地塞米松抑制的敏感性显著相关。孵育 24 小时后,在大鼠垂体培养物中观察到 preproTRH(178-199) 对 ACTH 分泌的显著抑制作用。本研究在一大系列人促肾上腺皮质激素肿瘤中进行,表明 preproTRH(178-199) 在相当大比例的标本中抑制肿瘤 ACTH 分泌,与肿瘤的大小及其对糖皮质激素负反馈的敏感性密切相关。这似乎是一个有前途的研究途径,需要进一步研究以探索 preproTRH(178-199) 作为 ACTH 分泌调节剂的全部范围。